Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry.

Francini E, Gray KP, Shaw GK, Evan CP, Hamid AA, Perry CE, Kantoff PW, Taplin ME, Sweeney CJ.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):420-427. doi: 10.1038/s41391-018-0121-2. Epub 2019 Jan 14.

PMID:
30643173
2.

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.

Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, Loda M, Corcoran NM, Van Allen EM, Choudhury AD, Sweeney CJ.

Eur Urol. 2019 Jul;76(1):89-97. doi: 10.1016/j.eururo.2018.11.045. Epub 2018 Dec 12.

PMID:
30553611
3.

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.

Francini E, Yip S, Ahmed S, Li H, Ardolino L, Evan CP, Kaymakcalan M, Shaw GK, Kantoff PW, Taplin ME, Alimohamed NS, Joshua AM, Heng DYC, Sweeney CJ.

Clin Genitourin Cancer. 2018 Apr;16(2):130-134. doi: 10.1016/j.clgc.2017.12.012. Epub 2017 Dec 27.

4.

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.

Muralidhar V, Regan MM, Werner L, Nakabayashi M, Evan CP, Bellmunt J, Choueiri TK, Elfiky AA, Harshman LC, McKay RR, Pomerantz MM, Sweeney CJ, Taplin ME, Kantoff PW, Nguyen PL.

Clin Genitourin Cancer. 2016 Aug;14(4):e299-305. doi: 10.1016/j.clgc.2015.12.008. Epub 2015 Dec 17.

PMID:
26778006
5.

Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease.

Tsao CK, Gray KP, Nakabayashi M, Evan C, Kantoff PW, Huang J, Galsky MD, Pomerantz M, Oh WK.

J Urol. 2015 Jul;194(1):91-7. doi: 10.1016/j.juro.2015.01.078. Epub 2015 Jan 24.

PMID:
25623747
6.

Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less.

Parekh A, Chen MH, Graham P, Mahal BA, Hirsch AE, Nakabayashi M, Evan C, Kantoff PW, Martin NE, Nguyen PL.

Clin Genitourin Cancer. 2015 Feb;13(1):e1-6. doi: 10.1016/j.clgc.2014.06.016. Epub 2014 Jun 27.

PMID:
25103271
7.

Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival.

Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ.

Prostate. 2014 Jun;74(8):820-8. doi: 10.1002/pros.22788. Epub 2014 Mar 26.

PMID:
24668612
8.

Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival.

Sharma J, Gray KP, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ.

Prostate. 2014 Feb;74(3):225-34. doi: 10.1002/pros.22744. Epub 2013 Oct 16.

PMID:
24132762
9.

Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality.

Pomerantz MM, Werner L, Xie W, Regan MM, Lee GS, Sun T, Evan C, Petrozziello G, Nakabayashi M, Oh WK, Kantoff PW, Freedman ML.

Cancer Prev Res (Phila). 2011 May;4(5):719-28. doi: 10.1158/1940-6207.CAPR-10-0292. Epub 2011 Mar 2.

10.

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.

Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antràs L, Smith M, Neary MP, Duh MS.

Cancer. 2007 Mar 15;109(6):1090-6.

11.

Development of an integrated prostate cancer research information system.

Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks J.

Clin Genitourin Cancer. 2006 Jun;5(1):61-6.

PMID:
16859581

Supplemental Content

Support Center